Incidence of metabolic syndrome in people with HIV who start dolutegravir based-regimen compared with bictegravir based-regimen after 48 weeks - Mata Marín, José Antonio; Rodríguez Evaristo, Mara Soraya; Cano Díaz, Ana Luz; Salinas Velázquez, Gloria Elizabeth; Triana González, Salma; Chaparro Sánchez, Alberto; Pompa Mera, Ericka; Meneses Cisneros, Betzahida; Gaytán Martínez, Jesús Enrique (AIDS (London), 2025)
Keywords: Adult; Amides; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Antiretroviral Therapy, Highly Active - adverse effects; Antiretroviral Therapy, Highly Active - methods; Female; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - therapeutic use; Heterocyclic Compounds, 4 or More Rings - administration & dosage; Heterocyclic Compounds, 4 or More Rings - adverse effects; Heterocyclic Compounds, 4 or More Rings - therapeutic use; HIV Infections - complications; HIV Infections - drug therapy; Humans; Incidence; Male; Metabolic Syndrome - chemically induced; Metabolic Syndrome - epidemiology; Middle Aged; Oxazines; Piperazines; Pyridones; metabolic syndrome; integrase strand transfer inhibitors; metabolic disturbances; weight gain